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Based on scientific literature, IBD is a chronic disease that does not have
any treatments without considerable side effects. The purpose of the
proposed drug polymer complex pH sensitive delivery system is to
reduce inflammation of the GI tract in Ulcerative Colitis and Crohn’s
Disease. The complex formulation has been shown using the
nanoprecipitation method with specific drug, polymers and stabilizer.
The organic phase was added to the aqueous phase and  homogenized, followed 
by a period of stirring to remove the solvent.
The nanoprecipitate method was utilized to form a drug polymer complex.
In future experimentation, this project contains optimizing the drug 
release from the polymer using the pH dissolution test, drug loading, 
drug coatings at a range of different pH of the GI tract for release at 
specific times, and mice studies.
Drug: Silymarin, Polymer: PLGA 502H, 1:4 
Solvents: Ethyl Acetate 7:3 Stabilizer: PVA
Silymarin Complex with PLGA Polymers as a Potential Drug Formulation 
for Intestinal track Inflammatory Diseases
Formation of precipitate 
after centrifuge.
Figure 1. (a) Effects of Crohn’s Disease & Ulcerative Colitis on GI 
Tract (b) Scope view of IBD
Crohn’s Disease and Ulcerative Colitis
are cumulatively known as
Inflammatory Bowel Disease (IBD),
they are distinguished by inflammation
in the gastrointestinal tract. A survey
from 2017 stated that 57% of IBD
patients were originally misdiagnosed,
since the symptoms can suggest many
things.1 Symptoms include2
Ø Cramps, Abdominal Pain
Ø Blood in stool
Ø Diarrhea, Constipation, bloating
Ø Visceral Hypersensitivity
Ø Fever, fatigue
Ø Unintended weight loss
Ø Intestinal Inflammation
As stated by Nature Reviews Gastroenterology & Hepatology, more than
one million people in the United states and over two and a half million
people in Europe are presumed to have IBD.3
Ø Since the twentieth century, Ulcerative Colitis and Crohn’s Disease
has significantly increased in the western world.
Ø The prevalence in the Western world has now increased to 0.5% of the
entire population.4
Ø Recently, IBD has evolved into a global disease and its prevalence in
every continent continues to grow exponentially.
(a) (b)
Objectives
Ø To develop a stable PLGAdrug polymer complex.








This figure shows the results obtained from taking an FTIR of the drug, polymer, 
stabilizer as well and complex.
The FTIR data shown in the results section demonstrates that the drug 
polymer complex was successfully produced. In the figure, the FTIR 
results of the drug- Silymarin is shown in blue. The polymer used is PLGA 
resomer 502H which is shown as the gray line in the graph. PLGA is 
composed of carboxylic groups, ester groups and methyl groups which can 
all be seen in the data. The stabilizer which is Polyvinyl Alcohol (PVA) is 
represented in yellow. The structures of each compound are shown below. 
The complex is shown in orange and demonstrates all the necessary peaks 
which correspond to the drug, polymer and stabilizer. From this we can 
conclude that the complex was successfully produced using the
nanoprecipitate method. 
Silymarin Structure Polyvinyl Alcohol Structure
PLGA 502H Structure
